IL2 and Autoimmunity: Low-dose IL-2 therapy, which preferentially expands Tregs, or the use of checkpoint inhibitors targeting co-stimulatory pathways involved in autoimmunity, may provide innovative strategies, though their application in AIG requires rigorous investigation [93].